Last updated on July 2018

Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Na ve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)


Brief description of study

The purpose of the study is to assess the efficacy of ALXN1210 to control disease activity in adolescent and adult patients with aHUS who have not previously used a complement inhibitor.

Clinical Study Identifier: NCT02949128

Contact Investigators or Research Sites near you

Start Over

Alexion Pharmaceuticals, Email for a ...

Clinical Trial Site
Barcelona, Spain